Displaying 2261 - 2280 of 2530
FTC Chairman Testifies Before Senate Committee on Merger Enforcement in the Gasoline Industry
Date
Federal Trade Commission Chairman Robert Pitofsky presented the Commission's testimony today before the Senate Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism of the Committee on...
FTC Charges Schering-Plough over Allegedly Anticompetitive Agreements with Two Other Drug Manufacturers
Date
The Federal Trade Commission today charged three drug makers, Schering-Plough Corporation ("Schering"), Upsher-Smith Laboratories ("Upsher-Smith") and American Home Products Corporation, with entering...
FTC to Host Workshop on Emerging Issues for Competition Policy in the E-Commerce Environment
Date
The Federal Trade Commission today announced that it will host a public workshop at its Washington D.C. headquarters on May 7 and 8 to explore certain competition issues that arise in connection with...
Public Statement
Report from the Bureau of Competition
Date
I. Introduction I appreciate the opportunity to present this overview of developments at the Bureau of Competition over the last twelve months. (1) I have the distinct honor of succeeding Rich Parker...
Public Statement
Antitrust and Intellectual Property: Unresolved Issues at the Heart of the New Economy
Date
A. INTRODUCTION The essential feature that is new about the "New Economy" is its increased dependence on products and services that are the embodiment of ideas. Examples include such diverse products...
FTC Reaches Record Financial Settlement To Settle Charges of Price-fixing in Generic Drug Market
Date
The Federal Trade Commission today approved a $100 million settlement with Mylan Laboratories, Inc., the largest monetary settlement in Commission history. If the settlement is approved by the federal...
Mylan Laboratories, Inc., Cambrex Corporation, Profarmaco S.R.I., and Gyma Laboratories of America, Inc.
Complaint filed in the U.S. District Court for the District of Columbia charged Mylan with restraint of trade, monopolization and conspiracy to monopolize the market for two generic drugs used to treat anxiety, lorazepam and clorazepate, through exclusive dealing arrangements. The Commission alleged that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. The complaint sought consumer redress of at least $120 million and to enjoin the alleged illegal exclusive licensing agreements. The district court upheld the Commission’s authority to seek restitution in antitrust injunction actions under Section 13(b). The Commission approved a $100 million settlement. The opinion settled Commission concerns that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. On February 1, 2002, the court granted approval to a plan of distribution to injured consumers who paid the increased prices and state agencies, including Medicaid programs, that purchased the drugs while the illegal agreements were in effect. The funds were distributed by the states.
Type of Action
Federal
Last Updated
FTC Matter/File Number
9810146
Public Statement
Antitrust Economics: Three Cheers and Two Challenges
Date
People who labor in and around the law are naturally wary of commentary that begins with praise. They have learned, for example, that appellate court opinions that start with references to the...
Public Statement
EU and U.S. Approaches to International Mergers--Views from the U.S. Federal Trade Commission
Date
It is a delight for me to participate in this panel on Merger Control in an International Context, and to join my enforcement colleagues and friends, Alex Schaub and Joel Klein, in this discussion...
Jun29
Workshop on Competition Policy in the World of B2B Electronic Marketplaces
-
The FTC held a public workshop to examine issues of competition policy that arise in connection with business-to-business ("B2B") electronic marketplaces.
May31
Workshop on Slotting Allowances and Other Grocery Marketing Practices
-
Slotting allowances are the lump-sum, up-front payments that manufacturers of food items often pay in order to get new products on supermarket shelves. The goals of the workshop were to provide a...
Public Statement
"The Nature and Limits of Restructuring in Merger Review"
Date
A. Introduction. In recent years, the enforcement agencies in their merger review have been offered more ambitious and complicated restructuring proposals to address overlaps and other potential anti...
FTC Preserves Competition in Market for Title Information Services
Date
The Federal Trade Commission has negotiated an agreement containing a proposed consent order designed to remedy the anticompetitive effects arising from Fidelity National Financial, Inc.'s ("FNF")...
Displaying 2261 - 2280 of 2530